Voluntary Activity Wheel Running Improves Hyperammonaemia‐Induced Skeletal Muscle Molecular and Metabolic Perturbations in Mice

ABSTRACT Aim Voluntary exercise improves clinical outcomes in healthy subjects, but increased muscle ammoniagenesis may limit beneficial responses during hyperammonaemia in chronic diseases. Responses to 4‐weeks voluntary wheel running (VWR) were compared with usual activity (UA) to determine if hyp...

Full description

Saved in:
Bibliographic Details
Published inJournal of cachexia, sarcopenia and muscle Vol. 16; no. 4; pp. e70031 - n/a
Main Authors Bellar, Annette, Kumar, Avinash, Chandramohan, Khaviyaa, Mishra, Saurabh, Alsabbagh‐Alchirazi, Muaz, Astafev, Artem, Kannan, Pugazhendhi, Attaway, Amy, Kondratov, Roman, Jaramillo, Thomas, Mishra, Lopa, Kasumov, Takhar, Welch, Nicole, Dasarathy, Srinivasan
Format Journal Article
LanguageEnglish
Published Germany John Wiley & Sons, Inc 01.08.2025
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Aim Voluntary exercise improves clinical outcomes in healthy subjects, but increased muscle ammoniagenesis may limit beneficial responses during hyperammonaemia in chronic diseases. Responses to 4‐weeks voluntary wheel running (VWR) were compared with usual activity (UA) to determine if hyperammonaemia alters VWR responses and if VWR alters muscle responses to hyperammonaemia. Methods Eight‐ to 10‐week‐old male C57BL/6J mice were treated with 6 weeks of subcutaneous infusion of 2.5 mmol kg−1 day−1 ammonium acetate (AmAc) or vehicle (PBS) via an osmotic pump. Two weeks after the start of infusion, mice were assigned to the intervention (VWR or UA). Wheel runs were measured, and weekly average rotations, distance, and circadian patterns were analysed. Indirect calorimetry was performed pre‐ and post‐intervention. Mice were euthanized 4 weeks after the start of VWR/UA, and organs (including muscles) were harvested, weighed, and muscle histomorphometry performed for fibre diameter/type. Protein synthesis by ex vivo puromycin incorporation, autophagy markers, expression of signalling proteins (mTORC1 pathway, eukaryotic initiation factor‐2‐α phosphorylation), and ammonia disposal enzymes were quantified by immunoblots. Mitochondrial oxidative function was measured by high‐sensitivity respirofluorometry using substrate, uncoupler, inhibitor, and titration protocols. Fluorometric assays were done for ammonia measurements. Results Gastrocnemius muscle mass (p < 0.01), muscle fibre area (p < 0.01), and grip strength were lower in AmAc‐UA than in PBS‐UA mice and higher with VWR than UA in AmAc mice (p < 0.001). Expression of electron transport chain proteins and some components of mitochondrial oxidative function were less (p < 0.05 or less) in AmAc‐UA than PBS‐UA, and these perturbations were reversed in the AmAc‐VWR mice (p < 0.05 or less). Global muscle protein synthesis (p < 0.05) and components of the mTORC1 pathway expression (p < 0.05) were higher, while myostatin expression was lower with VWR than UA in AmAc mice (p < 0.05). Expression of autophagy markers P62 and LC3‐II was not different with VWR or UA in AmAc mice, while Beclin1 was higher in VWR compared with UA, regardless of treatment group (p < 0.001). Expression of muscle ammonia disposal pathway enzymes, including glutamate dehydrogenase and pyrroline‐5‐carboxylate synthase, was higher (p ≤ 0.05) in AmAc‐UA versus PBS‐UA and increased in only PBS‐VWR mice (p < 0.05). Conclusion VWR reverses hyperammonaemia‐induced sarcopenia, protein synthesis/autophagy signalling perturbations, and mitochondrial oxidative dysfunction. Muscle mass, grip strength, signalling, and mitochondrial responses to VWR were not affected by hyperammonaemia. Increased expression of enzymes involved in the ammonia disposal pathway in skeletal muscle may be an adaptive response to hyperammonaemia. These data provide the rationale for exercise programmes in chronic diseases, including cirrhosis, even with hyperammonaemia.
Bibliography:This work was funded in part by NIH R01 GM119174; R01 DK113196; P50 AA024333; R01 AA021890; 3U01AA026976; U01 AA 026976; R56HL141744; U01 DK061732; 5U01 DK062470‐17S2; R21 AR 071046. Nicole Welch is partially supported by NIH K08 AA028794 and the American College of Gastroenterology Clinical Research. A.H.A. and N.W. were supported by K12 HL141952. The Fusion Lumos instrument was purchased via an NIH‐shared instrument grant, 1S10OD023436‐01.
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Funding: This work was funded in part by NIH R01 GM119174; R01 DK113196; P50 AA024333; R01 AA021890; 3U01AA026976; U01 AA 026976; R56HL141744; U01 DK061732; 5U01 DK062470‐17S2; R21 AR 071046. Nicole Welch is partially supported by NIH K08 AA028794 and the American College of Gastroenterology Clinical Research. A.H.A. and N.W. were supported by K12 HL141952. The Fusion Lumos instrument was purchased via an NIH‐shared instrument grant, 1S10OD023436‐01.
ISSN:2190-5991
2190-6009
2190-6009
DOI:10.1002/jcsm.70031